Yingcheng Lin

机构：Shantou University, Cancer Hospital of Shantou University Medical College · ORCID：0000-0002-7477-0695

发表论文 62 篇 · 总被引 681 次 · h-index 11

代表论文

• Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial (2024 · Signal Transduction and Targeted Therapy · 被引 36)
• Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b Study (2022 · Journal of Thoracic Oncology · 被引 31)
• Metronomic therapy in advanced breast cancer and NSCLC: vinorelbine as a paradigm of recent progress (2020 · Expert Review of Anticancer Therapy · 被引 24)
• Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study (2025 · The Lancet Respiratory Medicine · 被引 17)
• Comprehensive Characterization of the Genomic Landscape in Chinese Pulmonary Neuroendocrine Tumors Reveals Prognostic and Therapeutic Markers (CSWOG-1901) (2022 · The Oncologist · 被引 14)
• The ABCG2 rs2231142 polymorphism and the risk of nephrolithiasis: A case–control study from the Taiwan biobank (2023 · Frontiers in Endocrinology · 被引 11)